or Try an Advanced Search...

    Technical Analysis for UNCY - Unicycive Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.04 0.97% 0.01
    UNCY closed up 0.97 percent on Friday, May 17, 2024, on 60 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical UNCY trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -3.70%
    NR7 Range Contraction -3.70%
    Narrow Range Bar Range Contraction -3.70%
    Inside Day Range Contraction -3.70%
    20 DMA Resistance Bearish -4.59%
    Outside Day Range Expansion -4.59%
    Gapped Up Strength -4.59%
    Fell Below 20 DMA Bearish -4.59%
    Older End-of-Day Signals for UNCY ...

       Recent Intraday Alerts

    Alert Time
    Fell Below Previous Day's Low 1 day ago
    Down 1% 1 day ago
    Up 1% 1 day ago
    Down 3% 2 days ago
    Down 2 % 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    UNCY Chart by TradingView
    Basic chart:

    Profile

    Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Kidney Disease Kidney Nephrology Organ Failure Acute Kidney Injury Hyperphosphatemia Chemical Entity

    Is UNCY a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 29 These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
    Mar 28 Unicycive Therapeutics GAAP EPS of -$1.28, revenue of $0.7M
    Mar 28 Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
    Mar 25 Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
    Mar 14 Unicycive rises 4% on $50M private placement
    Mar 14 Unicycive Announces $50 Million Private Placement
    Mar 13 Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
    Mar 7 Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
    Feb 14 Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
    Jan 24 Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
    See more UNCY news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.82
    52 Week Low 0.47
    Average Volume 368,754
    200-Day Moving Average 0.94
    50-Day Moving Average 1.25
    20-Day Moving Average 1.10
    10-Day Moving Average 1.10
    Average True Range 0.09
    RSI (14) 40.83
    ADX 11.98
    +DI 16.43
    -DI 23.65
    Chandelier Exit (Long, 3 ATRs) 1.02
    Chandelier Exit (Short, 3 ATRs) 1.20
    Upper Bollinger Bands 1.22
    Lower Bollinger Band 0.98
    Percent B (%b) 0.24
    BandWidth 21.05
    MACD Line -0.05
    MACD Signal Line -0.05
    MACD Histogram 0.0006
    Fundamentals Value
    Market Cap 36.14 Million
    Num Shares 34.8 Million
    EPS -1.47
    Price-to-Earnings (P/E) Ratio -0.71
    Price-to-Sales 57.15
    Price-to-Book 11.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.12
    Resistance 3 (R3) 1.11 1.09 1.10
    Resistance 2 (R2) 1.09 1.07 1.09 1.10
    Resistance 1 (R1) 1.06 1.06 1.05 1.07 1.09
    Pivot Point 1.04 1.04 1.03 1.04 1.04
    Support 1 (S1) 1.01 1.02 1.00 1.02 0.99
    Support 2 (S2) 0.99 1.01 0.99 0.98
    Support 3 (S3) 0.96 0.99 0.98
    Support 4 (S4) 0.97